X0306 4 2021-03-30 0 0001835579 Ikena Oncology, Inc. IKNA 0001361712 Stampacchia Otello C/O IKENA ONCOLOGY, INC. 645 SUMMER STREET, SUITE 101 BOSTON MA 02210 1 0 0 0 Common Stock 2021-03-30 4 C 0 1799123 A 1799123 I By Omega Fund VI, L.P. Common Stock 2021-03-30 4 A 0 450000 16.00 A 2249123 I By Omega Fund VI, L.P. Series B Preferred Stock 2020-12-21 4 A 0 12870933 1.3985 A Common Stock 1799123 12870933 I By Omega Fund VI, L.P. Series B Preferred Stock 2021-03-30 4 C 0 12870933 D Common Stock 1799123 0 I By Omega Fund VI, L.P. Each share of Series B Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Shares held directly by Omega Fund VI, L.P. ("Omega VI"). Omega Fund VI GP, L.P. ("Omega VI GP") is the sole general partner of Omega VI. Omega Fund VI GP Manager, Ltd. ("Omega VI Manager") is the sole general partner of Omega VI GP. The Reporting Person is a director of Omega VI Manager and disclaims beneficial ownership of the shares held by Omega VI except to the extent of his pecuniary interest therein, if any. This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. /s/ Otello Stampacchia 2021-04-01